Finding new treatments for acute myeloid leukemia using allosteric inhibitors.
Official title: Discovery and Development of Allosteric Inhibitors of Src-family Kinases for AML
Funded at University of Pittsburgh at Pittsburgh · NIH-11103819 · Data updated 2026-11-12
This study is looking at new medications that can help people with acute myeloid leukemia (AML) by blocking certain proteins that help cancer cells grow, with the hope of making treatments work better and preventing the cancer from becoming resistant to them.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $185,831 |
| NIH project number | 1R21CA291724-01A1 |
| Project ID | NIH-11103819 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia who may benefit from new treatment options.
✕Less likely to help
Patients with other types of leukemia or those who do not have acute myeloid leukemia may not receive any benefit from this research.
What this research studies
This research focuses on developing new drugs that target specific proteins involved in acute myeloid leukemia (AML), a serious type of blood cancer. The approach involves creating allosteric inhibitors that can effectively block the activity of certain kinases, which are proteins that help cancer cells grow. By targeting these proteins, the researchers aim to prevent the cancer cells from developing resistance to existing treatments. This innovative strategy could lead to more effective therapies for patients with AML.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with acute myeloid leukemia, potentially improving survival rates.
How similar studies have gone: Previous research has shown success with similar approaches in targeting kinases, indicating potential for this novel strategy.
Where this research is happening
-
University of Pittsburgh at Pittsburgh
Pittsburgh, United States Active
Researchers
- Principal investigator: Smithgall, Thomas E. — University of Pittsburgh at Pittsburgh
- Study coordinator: Smithgall, Thomas E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.